A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

Inclusion Criteria:

- Histologically or cytologically confirmed extensive-stage small-cell lung cancer
(SCLC).

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

- Adequate hematologic and organ function as confirmed by laboratory values

Exclusion Criteria:

- Clinically significant cardiac abnormalities including QRS duration of >120 msec; QTcF
>470 msec for women and >450 msec for men; Abnormal cardiac rhythm; Clinically
significant cardiac valve abnormality; Documented history of left ventricular ejection
fraction <0.30 within 6 months; Permanent pacemaker or automatic implantable
cardioverter defibrillator; History of torsades de pointes, congenital long QT
syndrome, or family history of long QT syndrome or sudden death

- Recent or ongoing serious infection

- Women who are pregnant or breastfeeding

- Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, prior participation in a
rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab
tesirine or excipient contained in the drug formulation.